Trovagene Inc (TROV) 4.65 $TROV
SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims against TrovaGene, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Wed Mar 30, 12:41PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by TrovaGene, Inc. ("TrovaGene" or the "Company"
(Nasdaq: TROV). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
TROV: 4.65 (-0.08)
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Trovagene, Inc. - TROV
PR Newswire - Wed Mar 30, 10:26AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Trovagene, Inc. ("Trovagene" or the "Company" (NASDAQ: TROV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
TROV: 4.65 (-0.08)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of TrovaGene, Inc.
BusinessWire - Wed Mar 30, 9:40AM CDT
Levi & Korsinsky announces it has commenced an investigation of TrovaGene, Inc. ("TrovaGene" or the "Company" (NASDAQ:TROV) concerning possible violations of federal securities laws by certain officers and directors.
TROV: 4.65 (-0.08)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims against TrovaGene, Inc. And Advises Investors With Losses In Excess of $50,000 To Contact The Firm
BusinessWire - Tue Mar 29, 5:41PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by TrovaGene, Inc. ("TrovaGene" or the "Company" (Nasdaq: TROV). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
TROV: 4.65 (-0.08)
Harwood Feffer LLP Announces Investigation of Trovagene, Inc.
PR Newswire - Tue Mar 29, 4:23PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Trovagene, Inc. ("Trovagene" or the "Company" (NASDAQ: TROV), concerning whether the board has breached its fiduciary duties to shareholders.
TROV: 4.65 (-0.08)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of TrovaGene, Inc. (TROV)
PR Newswire - Tue Mar 29, 2:07PM CDT
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of TrovaGene, Inc. ("TrovaGene" or "the Company" (NASDAQ: TROV). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
TROV: 4.65 (-0.08)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Trovagene, Inc. - TROV
BusinessWire - Tue Mar 29, 12:23PM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Trovagene, Inc. (NASDAQ:TROV) resulting from allegations that Trovagene may have issued materially misleading business information to the investing public.
TROV: 4.65 (-0.08)
TrovaGene Plunges on CEO and CFO Dismissal; Files Suit
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 11:20AM CDT
Shares of TrovaGene Inc. (TROV) plunged 46.2% after the company's board dismissed its CEO and CFO.
ABMD: 94.81 (+1.78), TROV: 4.65 (-0.08), EW: 88.21 (-0.68), LMNX: 19.40 (-0.09)
Trovagene Shareholder (TROV) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Trovagene, Inc.; Encourages Investors to Contact the Firm
PR Newswire - Tue Mar 29, 7:44AM CDT
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Trovagene, Inc. (NASDAQ: TROV). Trovagene a molecular diagnostic company focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines.
TROV: 4.65 (-0.08)
Trovagene Interim CEO to Host Investor Conference Call
PR Newswire - Tue Mar 29, 7:36AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Trovagene's interim CEO Thomas Adams, Ph.D., will host an investor conference call on Tuesday, March, 29, 2016 at 9:00 a.m. Eastern Daylight Time (6:00 a.m. Pacific Daylight Time).
TROV: 4.65 (-0.08)
Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause
PR Newswire - Mon Mar 28, 6:30PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that its Board of Directors terminated the employment of CEO Antonius Schuh and CFO Stephen Zaniboni for cause and has filed a complaint against Dr. Schuh and Mr. Zaniboni for, among other things, breach of fiduciary duty. The complaint was filed in the Superior Court of the State of California for the County of San Diego. Trovagene alleges that Dr. Schuh and Mr. Zaniboni failed to present a lucrative corporate opportunity to Trovagene concerning promising new therapeutics in the field of precision medicine and instead took that opportunity for their own personal benefit. The complaint asks that Dr. Schuh and Mr. Zaniboni be required to turn over their interests in these new therapeutics to Trovagene. Concurrently, the Board has appointed Dr. Thomas Adams, the Company's Chairman of the Board, as CEO on an interim basis. All changes are effective immediately. Dr. Adams remarked, "The acquisition of new therapeutics in the field of precision medicine presents an exciting opportunity for Trovagene and we intend to bring that opportunity to Trovagene where it rightfully belongs for the good of our shareholders."
TROV: 4.65 (-0.08)
Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016
PR Newswire - Thu Mar 24, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical results for the Company's Precision Cancer Monitoring® platform will be presented by Dr. Takeo Fujii of the University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2016.
TROV: 4.65 (-0.08)
Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies
ACCESSWIRE - Mon Mar 21, 12:25PM CDT
WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or "WBT" , is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space.
CSII: 10.37 (+0.23), TROV: 4.65 (-0.08)
TrovaGene (TROV) Falls on Wider-than-Expected Q4 Loss
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 8:20AM CST
TrovaGene Inc (TROV) reported adjusted loss of 27 cents per share in the fourth quarter of 2015, wider than the year-ago loss of 25 cents.
ABMD: 94.81 (+1.78), TROV: 4.65 (-0.08), LMNX: 19.40 (-0.09), CRY: 10.75 (-0.40)
/C O R R E C T I O N -- Trovagene, Inc./
PR Newswire - Thu Mar 10, 10:40PM CST
In the news release, Trovagene Announces Fourth Quarter and Year End 2015 Financial Results, issued 10-Mar-2016 by Trovagene, Inc. over PR Newswire, we are advised by the company that in the Condensed Consolidated Statements of Operations table, in the Diagnostic service revenue and Other revenue line items, under the Three Months Ended December 31, 2015 column, the numbers should read "3" and "24", respectively, rather than "24" and "3", as originally issued inadvertently. The complete, corrected release follows:
TROV: 4.65 (-0.08)
Trovagene reports 4Q loss
Automated Insights - Thu Mar 10, 5:17PM CST
SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Thursday reported a loss of $7.4 million in its fourth quarter.
TROV: 4.65 (-0.08)
Trovagene Announces Fourth Quarter and Year End 2015 Financial Results
PR Newswire - Thu Mar 10, 3:13PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and year ended December 31, 2015.
TROV: 4.65 (-0.08)
Presentation at the Molecular Medicine Tri-Conference to Highlight Clinical Performance of Trovagene's Precision Cancer Monitoring Platform
PR Newswire - Tue Mar 08, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will be presenting at the Molecular Medicine Tri-Conference 2016, highlighting clinical performance of the Company's Precision Cancer Monitoring® (PCM) technology and how high sensitivity and the ability to quantitate mutational load translates into clinical applications for treating late-stage cancer patients. Vlada Melnikova, M.D., Ph.D., will deliver the presentation on March 10, 2016 at 12:15 p.m. (PST) in San Francisco, CA. The presentation, entitled Pharmacodynamic Assessment of Drug Response by Monitoring Mutational Load in Urinary Circulating Tumor DNA, will feature data from clinical studies in both lung and pancreatic cancer.
TROV: 4.65 (-0.08)
What's in Store for TrovaGene (TROV) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:00AM CST
TrovaGene Inc. (TROV) is scheduled to report fourth-quarter 2015 earnings results on Mar 10.
TROV: 4.65 (-0.08), KMDA: 3.83 (-0.08), AMGN: 149.93 (+0.45), MDXG: 8.74 (+0.17)
Franklin Square Provides Financing for New Mountain Capital's Acquisitions and Combination of Trover Solutions and Equian
PR Newswire - Thu Mar 03, 7:00AM CST
Franklin Square Capital Partners, the largest manager of business development companies (BDCs), announced the origination of a $260 million unitranche term loan to support the acquisition and combination of Trover Solutions, Inc. and Equian LLC by New Mountain Capital, LLC (New Mountain), a New York-based alternative investments firm that manages approximately $15 billion of private equity, public equity and credit assets.
TROV: 4.65 (-0.08), FSIC: 9.17 (+0.02)
SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims against TrovaGene, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Wed Mar 30, 12:41PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by TrovaGene, Inc. ("TrovaGene" or the "Company"
(Nasdaq: TROV). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. TROV: 4.65 (-0.08)
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Trovagene, Inc. - TROV
PR Newswire - Wed Mar 30, 10:26AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Trovagene, Inc. ("Trovagene" or the "Company"
(NASDAQ: TROV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. TROV: 4.65 (-0.08)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of TrovaGene, Inc.
BusinessWire - Wed Mar 30, 9:40AM CDT
Levi & Korsinsky announces it has commenced an investigation of TrovaGene, Inc. ("TrovaGene" or the "Company"
(NASDAQ:TROV) concerning possible violations of federal securities laws by certain officers and directors. TROV: 4.65 (-0.08)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims against TrovaGene, Inc. And Advises Investors With Losses In Excess of $50,000 To Contact The Firm
BusinessWire - Tue Mar 29, 5:41PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by TrovaGene, Inc. ("TrovaGene" or the "Company"
(Nasdaq: TROV). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. TROV: 4.65 (-0.08)
Harwood Feffer LLP Announces Investigation of Trovagene, Inc.
PR Newswire - Tue Mar 29, 4:23PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Trovagene, Inc. ("Trovagene" or the "Company"
(NASDAQ: TROV), concerning whether the board has breached its fiduciary duties to shareholders. TROV: 4.65 (-0.08)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of TrovaGene, Inc. (TROV)
PR Newswire - Tue Mar 29, 2:07PM CDT
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of TrovaGene, Inc. ("TrovaGene" or "the Company"
(NASDAQ: TROV). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. TROV: 4.65 (-0.08)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Trovagene, Inc. - TROV
BusinessWire - Tue Mar 29, 12:23PM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Trovagene, Inc. (NASDAQ:TROV) resulting from allegations that Trovagene may have issued materially misleading business information to the investing public.
TROV: 4.65 (-0.08)
TrovaGene Plunges on CEO and CFO Dismissal; Files Suit
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 11:20AM CDT
Shares of TrovaGene Inc. (TROV) plunged 46.2% after the company's board dismissed its CEO and CFO.
ABMD: 94.81 (+1.78), TROV: 4.65 (-0.08), EW: 88.21 (-0.68), LMNX: 19.40 (-0.09)
Trovagene Shareholder (TROV) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Trovagene, Inc.; Encourages Investors to Contact the Firm
PR Newswire - Tue Mar 29, 7:44AM CDT
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Trovagene, Inc. (NASDAQ: TROV). Trovagene a molecular diagnostic company focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines.
TROV: 4.65 (-0.08)
Trovagene Interim CEO to Host Investor Conference Call
PR Newswire - Tue Mar 29, 7:36AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Trovagene's interim CEO Thomas Adams, Ph.D., will host an investor conference call on Tuesday, March, 29, 2016 at 9:00 a.m. Eastern Daylight Time (6:00 a.m. Pacific Daylight Time).
TROV: 4.65 (-0.08)
Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause
PR Newswire - Mon Mar 28, 6:30PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that its Board of Directors terminated the employment of CEO Antonius Schuh and CFO Stephen Zaniboni for cause and has filed a complaint against Dr. Schuh and Mr. Zaniboni for, among other things, breach of fiduciary duty. The complaint was filed in the Superior Court of the State of California for the County of San Diego. Trovagene alleges that Dr. Schuh and Mr. Zaniboni failed to present a lucrative corporate opportunity to Trovagene concerning promising new therapeutics in the field of precision medicine and instead took that opportunity for their own personal benefit. The complaint asks that Dr. Schuh and Mr. Zaniboni be required to turn over their interests in these new therapeutics to Trovagene. Concurrently, the Board has appointed Dr. Thomas Adams, the Company's Chairman of the Board, as CEO on an interim basis. All changes are effective immediately. Dr. Adams remarked, "The acquisition of new therapeutics in the field of precision medicine presents an exciting opportunity for Trovagene and we intend to bring that opportunity to Trovagene where it rightfully belongs for the good of our shareholders."
TROV: 4.65 (-0.08)
Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016
PR Newswire - Thu Mar 24, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical results for the Company's Precision Cancer Monitoring® platform will be presented by Dr. Takeo Fujii of the University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2016.
TROV: 4.65 (-0.08)
Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies
ACCESSWIRE - Mon Mar 21, 12:25PM CDT
WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or "WBT"
, is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space. CSII: 10.37 (+0.23), TROV: 4.65 (-0.08)
TrovaGene (TROV) Falls on Wider-than-Expected Q4 Loss
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 8:20AM CST
TrovaGene Inc (TROV) reported adjusted loss of 27 cents per share in the fourth quarter of 2015, wider than the year-ago loss of 25 cents.
ABMD: 94.81 (+1.78), TROV: 4.65 (-0.08), LMNX: 19.40 (-0.09), CRY: 10.75 (-0.40)
/C O R R E C T I O N -- Trovagene, Inc./
PR Newswire - Thu Mar 10, 10:40PM CST
In the news release, Trovagene Announces Fourth Quarter and Year End 2015 Financial Results, issued 10-Mar-2016 by Trovagene, Inc. over PR Newswire, we are advised by the company that in the Condensed Consolidated Statements of Operations table, in the Diagnostic service revenue and Other revenue line items, under the Three Months Ended December 31, 2015 column, the numbers should read "3" and "24", respectively, rather than "24" and "3", as originally issued inadvertently. The complete, corrected release follows:
TROV: 4.65 (-0.08)
Trovagene reports 4Q loss
Automated Insights - Thu Mar 10, 5:17PM CST
SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Thursday reported a loss of $7.4 million in its fourth quarter.
TROV: 4.65 (-0.08)
Trovagene Announces Fourth Quarter and Year End 2015 Financial Results
PR Newswire - Thu Mar 10, 3:13PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and year ended December 31, 2015.
TROV: 4.65 (-0.08)
Presentation at the Molecular Medicine Tri-Conference to Highlight Clinical Performance of Trovagene's Precision Cancer Monitoring Platform
PR Newswire - Tue Mar 08, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will be presenting at the Molecular Medicine Tri-Conference 2016, highlighting clinical performance of the Company's Precision Cancer Monitoring® (PCM) technology and how high sensitivity and the ability to quantitate mutational load translates into clinical applications for treating late-stage cancer patients. Vlada Melnikova, M.D., Ph.D., will deliver the presentation on March 10, 2016 at 12:15 p.m. (PST) in San Francisco, CA. The presentation, entitled Pharmacodynamic Assessment of Drug Response by Monitoring Mutational Load in Urinary Circulating Tumor DNA, will feature data from clinical studies in both lung and pancreatic cancer.
TROV: 4.65 (-0.08)
What's in Store for TrovaGene (TROV) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:00AM CST
TrovaGene Inc. (TROV) is scheduled to report fourth-quarter 2015 earnings results on Mar 10.
TROV: 4.65 (-0.08), KMDA: 3.83 (-0.08), AMGN: 149.93 (+0.45), MDXG: 8.74 (+0.17)
Franklin Square Provides Financing for New Mountain Capital's Acquisitions and Combination of Trover Solutions and Equian
PR Newswire - Thu Mar 03, 7:00AM CST
Franklin Square Capital Partners, the largest manager of business development companies (BDCs), announced the origination of a $260 million unitranche term loan to support the acquisition and combination of Trover Solutions, Inc. and Equian LLC by New Mountain Capital, LLC (New Mountain), a New York-based alternative investments firm that manages approximately $15 billion of private equity, public equity and credit assets.
TROV: 4.65 (-0.08), FSIC: 9.17 (+0.02)
